BOLT Bolt Biotherapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1641281 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-51.3%
TTM net income YoY38.7%
TTM EPS YoY37.1%
Revenue 3-yr CAGR-29.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,098.0%
Net margin-1,034.4%
FCF margin—
EBITDA margin-1,068.0%
Returns
ROE-128.8%
ROA-52.0%
ROIC (approx.)-481.0%
Asset turnover0.05x
Leverage & solvency
Liabilities / assets75.9%
Debt / equity0.00x
Current ratio2.05x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-2.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.70M | $7.69M | $7.88M | $5.73M | $1.26M |
| R&D expense | $28.53M | $57.47M | $61.54M | $73.12M | $75.66M |
| SG&A expense | $13.79M | $18.46M | $22.53M | $22.93M | $18.39M |
| Operating income | -$36.11M | -$73.05M | -$76.20M | -$90.32M | -$92.79M |
| Pretax income | -$33.38M | -$63.12M | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33.38M | -$63.12M | -$69.20M | -$88.10M | -$98.59M |
| EBITDA | -$34.82M | -$71.27M | -$74.34M | -$88.66M | -$91.59M |
| EPS (basic) | -17.85 | -33.06 | -1.83 | -2.36 | -2.97 |
| EPS (diluted) | -17.85 | -33.06 | -1.83 | -2.36 | -2.97 |
| Weighted avg. shares (diluted) | 1.87M | 1.91M | 37.81M | 37.36M | 33.20M |
| Balance sheet | |||||
| Cash & equivalents | $11.70M | $7.21M | $10.81M | $9.24M | $27.38M |
| Short-term investments | $15.80M | $40.12M | $91.38M | $159.64M | $158.84M |
| Current assets | $30.26M | $50.81M | $105.71M | $172.75M | $189.16M |
| PP&E, net | $1.25M | $3.14M | $4.96M | $6.45M | $6.16M |
| Total assets | $56.75M | $99.63M | $159.78M | $227.81M | $307.72M |
| Current liabilities | $8.44M | $15.86M | $20.46M | $23.12M | $21.33M |
| Total liabilities | $30.24M | $42.43M | $47.04M | $56.30M | $57.60M |
| Shareholders' equity | $26.50M | $57.20M | $112.74M | $171.51M | $250.12M |
| Shares outstanding | 1.92M | 1.92M | 38.11M | 37.80M | 37.40M |
| Cash flow statement | |||||
| Operating cash flow | -$39.85M | -$61.29M | -$69.53M | -$76.50M | -$57.07M |
| Capital expenditure | $72,000 | $41,000 | $206,000 | $1.95M | $2.34M |
| Free cash flow | -$39.92M | -$61.33M | -$69.73M | -$78.46M | -$59.40M |
| Investing cash flow | $44.30M | $57.58M | $71.04M | $57.86M | -$232.20M |
| Financing cash flow | $19,000 | $108,000 | $253,000 | $503,000 | $311.11M |
| Depreciation & amortization | $1.29M | $1.78M | $1.85M | $1.67M | $1.19M |
| Stock-based compensation | $2.78M | $7.41M | $9.22M | $9.58M | $8.50M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.